liraglutide / Generic mfg. 
Welcome,         Profile    Billing    Logout  
 112 Diseases   125 Trials   125 Trials   6082 News 


«12345678910111213...6465»
  • ||||||||||  liraglutide / Generic mfg.
    Journal:  Characterization of glucagon-like peptide-1 (GLP-1) agonist exposures reported to a single United States poison center. (Pubmed Central) -  Feb 18, 2025   
    With reports of the acquisition of these medications through online platforms and poorly regulated compounding sources, this trend may pose public health risks. This study demonstrates the increasing incidence of glucagon-like peptide-1 agonist exposures reported to a United States regional poison center, predominantly due to unintentional overdoses, which highlights the need for ongoing patient education.
  • ||||||||||  liraglutide / Generic mfg., Trulicity (dulaglutide) / Eli Lilly
    Journal:  Prognostic Benefit of GLP-1 RA Addition to SGLT2i in Patients with ASCVD and Heart Failure: A Cohort Study. (Pubmed Central) -  Feb 18, 2025   
    This study demonstrates the increasing incidence of glucagon-like peptide-1 agonist exposures reported to a United States regional poison center, predominantly due to unintentional overdoses, which highlights the need for ongoing patient education. In ASCVD and HF patients, adding GLP-1 RA to SGLT2i reduces one-year mortality and hospitalization, warranting further investigation in diverse settings.
  • ||||||||||  Byetta (exenatide) / AstraZeneca, Adlyxin (lixisenatide) / Sanofi, Mounjaro (tirzepatide) / Eli Lilly
    Review, Journal:  Association of Glucagon-Like Peptide-1 Receptor Agonists (GLP-1 RAs) and Neurogenesis: A Systematic Review. (Pubmed Central) -  Feb 14, 2025   
    GLP-1 and GLP-1 RAs are positively associated with neurogenesis. This effect may have translational implications insofar as disparate mental disorders that are characterized by neurogenesis defects (e.g. depressive disorders and neurocognitive disorders) may be benefitted by these agents.
  • ||||||||||  liraglutide / Generic mfg., Ozempic (semaglutide SC once-weekly) / Novo Nordisk
    Clinical, Retrospective data, Review, Journal:  Once-Weekly Semaglutide Versus Once-Daily Liraglutide for Weight Loss in Adults: A Meta-Analysis of Randomized Controlled Trials. (Pubmed Central) -  Feb 11, 2025   
    The risk of severe adverse effects (OR, 1.66; 95% CI, 0.53-5.16; p?=?0.38) and gastrointestinal adverse effects (OR, 1.84; 95% CI, 0.82-4.14; p?=?0.14) was comparable between both groups. Once-weekly semaglutide therapy results in a more pronounced loss in body weight, HbA1c, and fasting glucose levels compared to once-daily liraglutide.
  • ||||||||||  liraglutide / Generic mfg.
    Clinical, Journal:  Liraglutide effects on epicardial adipose tissue micro-RNAs and intra-operative glucose control. (Pubmed Central) -  Feb 9, 2025   
    Our study shows that CORO- and LA-miRNAs profiles were significantly different than SAT miRNAs in overall patients and miRNAs were significantly higher in CORO-EAT and LA-EAT than SAT in the liraglutide group. Pre-op liraglutide was also associated with better intra operative glucose control than placebo independently of weight loss.
  • ||||||||||  Jardiance (empagliflozin) / Eli Lilly, Boehringer Ingelheim
    Review, Journal:  The mechanism and treatment of cognitive dysfunction in diabetes: A review. (Pubmed Central) -  Feb 7, 2025   
    Self-management, indirect fasting and repetitive transverse magnetic stimulation can also ameliorate cognitive impairment. In this review, we discuss the mechanisms linking diabetes mellitus with cognitive dysfunction and propose a potential treatment for cognitive dysfunction related to diabetes mellitus.
  • ||||||||||  liraglutide / Generic mfg., Mounjaro (tirzepatide) / Eli Lilly, Yishengtai (beinaglutide) / Shanghai Benemae Pharma
    Review, Journal:  An exploratory analysis of glucagon-like peptide-1 (GLP-1) agonists and biosimilars: A literature review. (Pubmed Central) -  Feb 6, 2025   
    With the growing popularity of GLP-1 RAs, accessibility and affordability remain a challenge as monthly costs without insurance for liraglutide, semaglutide and tirzepatide are $1418, $892, and $974 respectively...Preliminary results from liraglutide biosimilars are promising, and several semaglutide biosimilars are currently being investigated. Future research should focus on conducting comparative head-to-head trials to determine the clinical outcomes between biosimilars and reference products.
  • ||||||||||  liraglutide / Generic mfg., Mounjaro (tirzepatide) / Eli Lilly
    Review, Journal:  Why does GLP-1 agonist combined with GIP and/or GCG agonist have greater weight loss effect than GLP-1 agonist alone in obese adults without type 2 diabetes? (Pubmed Central) -  Feb 6, 2025   
    As glucagon-like peptide-1 (GLP-1) agonist approved by the Food and Drug Administration (FDA) for long-term weight management in adults with obesity, liraglutide and semaglutide have great weight loss effect through reducing food intake and delaying gastric emptying...The dual agonist tirzepatide activates both GLP-1 and glucose-dependent insulinotropic polypeptide (GIP) receptors and has shown enhanced potency for weight loss compared to conventional GLP-1 mono agonist...This review summarizes the comprehensive mechanisms underlying the pronounced advantages of GLP-1/GIP dual agonist, GLP-1/GCG dual agonist and GLP-1/GIP/GCG triple agonist over GLP-1 mono agonist in weight reduction in obese adults without type 2 diabetes. A deeper understanding of these unimolecular multitargeting GLP-1-based agonists will provide insights for their clinical application and guide the development of new drugs for obesity treatment.
  • ||||||||||  liraglutide / Generic mfg.
    Mitigation of Cochlear Damage With Liraglutide Treatment in Chinchillas Exposed to Repeated Blasts (Peninsula Ballroom) -  Feb 5, 2025 - Abstract #ARO2025ARO_387;    
    Liraglutide administration mitigates blast-induced cochlear damage, preserving hair cells and spiral ganglion neurons and therefore promoting hearing function restoration. Further research is needed to explore liraglutide's full impact on cochlear pathology and its potential as a therapeutic intervention for blast-induced hearing loss.
  • ||||||||||  liraglutide / Generic mfg.
    Preclinical, Journal:  High dose of liraglutide impairs renal function in female hypertensive rats. (Pubmed Central) -  Feb 5, 2025   
    Both doses' effects were independent of blood pressure and glycemic control. liraglutide appears to have distinct effects on the hypertensive female kidney depending on the dose, with higher doses impairing kidney function.
  • ||||||||||  liraglutide / Generic mfg.
    Journal:  Liraglutide for Children 6 to <12 Years of Age with Obesity - A Randomized Trial. (Pubmed Central) -  Feb 5, 2025   
    P3
    Among children (6 to <12 years of age) with obesity, treatment with liraglutide for 56 weeks plus lifestyle interventions resulted in a greater reduction in BMI than placebo plus lifestyle interventions. (Funded by Novo Nordisk; SCALE Kids ClinicalTrials.gov number, NCT04775082.).
  • ||||||||||  liraglutide / Generic mfg.
    Journal:  Effects of tryptophan-selective lipidated GLP-1 peptides on the GLP-1 receptor. (Pubmed Central) -  Feb 1, 2025   
    Under high-fat diet feeding, both long-term administration of peptide A and peptide B improved glucose tolerance and insulin sensitivity similarly to liraglutide. Thus, tryptophan-selective lipidated GLP-1 peptides are as effective as conventional GLP-1 RAs in reducing plasma glucose levels and body weight and may represent a less demanding method of manufacture of GLP-1 RAs.
  • ||||||||||  liraglutide / Generic mfg.
    FDA event, Journal:  FDA Approves Generic Liraglutide to Address GLP-1 Drug Shortage. (Pubmed Central) -  Jan 31, 2025   
    Thus, tryptophan-selective lipidated GLP-1 peptides are as effective as conventional GLP-1 RAs in reducing plasma glucose levels and body weight and may represent a less demanding method of manufacture of GLP-1 RAs. No abstract available
  • ||||||||||  liraglutide / Generic mfg., Mounjaro (tirzepatide) / Eli Lilly
    Retrospective data, Journal:  Discontinuation and Reinitiation of Dual-Labeled GLP-1 Receptor Agonists Among US Adults With Overweight or Obesity. (Pubmed Central) -  Jan 31, 2025   
    In this cohort study, most patients with overweight or obesity discontinued GLP-1 RA therapy within 1 year, but those without type 2 diabetes had higher discontinuation rates and lower reinitiation rates. Inequities in access and adherence to effective treatments have the potential to exacerbate disparities in obesity.
  • ||||||||||  liraglutide subcutaneous prolonged-release (NEX-22) / Nanexa AB
    Trial completion date, Trial primary completion date:  Phase 1 Study Assessing the Pharmacokinetics of NEX-22A in Subjects With T2D (clinicaltrials.gov) -  Jan 23, 2025   
    P1,  N=9, Active, not recruiting, 
    Although nearly one-half of all patients in a large health care system were AOM-eligible by guidelines and regulatory labeling, only 1% of those who were eligible were prescribed AOMs. Trial completion date: Nov 2024 --> May 2025 | Trial primary completion date: Nov 2024 --> May 2025
  • ||||||||||  retatrutide (LY3437943) / Eli Lilly, Mounjaro (tirzepatide) / Eli Lilly
    Preclinical, Journal:  Comparison of the effects of Liraglutide, Tirzepatide, and Retatrutide on diabetic kidney disease in db/db mice. (Pubmed Central) -  Jan 17, 2025   
    Retatrutide was the most effective in improving DKD and body weight, while Tirzepatide was the most effective in controlling blood glucose. Inhibiting the expression of inflammatory factors and fibrosis mediators and regulating intestinal microbiota may be the potential mechanisms of these two drugs to delay the progression of DKD.
  • ||||||||||  liraglutide / Generic mfg.
    Enrollment open, Trial completion date, Trial primary completion date:  Liraglutide-bolus vs Glargine-bolus Therapy in Overweight/Obese Type 2 Diabetes Patients (LiraGooD) (clinicaltrials.gov) -  Jan 13, 2025   
    P4,  N=164, Recruiting, 
    These findings may provide new therapeutic strategies for patients with diabetic kidney disease. Unknown status --> Recruiting | Trial completion date: Dec 2021 --> Feb 2025 | Trial primary completion date: Dec 2021 --> Jan 2025
  • ||||||||||  liraglutide / Generic mfg.
    Preclinical, Journal:  Pro-healing impact of liraglutide on skin wounds in normoglycemic mice. (Pubmed Central) -  Jan 12, 2025   
    We further identified that M2a macrophages predominantly presented in the early and middle stages of inflammation phase and M2d macrophages presented in the middle and late stages. Our study suggested that GLP-1RA liraglutide could promote wound healing in normoglycemic mice, which is partly attributed to the modulation of the macrophage polarization from M1 subtype to M2 subtype.
  • ||||||||||  liraglutide / Generic mfg., Trulicity (dulaglutide) / Eli Lilly
    Journal:  Differential Effects of GLP-1 Receptor Agonists on Cancer Risk in Obesity: A Nationwide Analysis of 1.1 Million Patients. (Pubmed Central) -  Jan 12, 2025   
    Conversely, liraglutide showed increased risks for thyroid (HR 1.70, 95% CI 1.03-2.82) and respiratory cancers (HR 1.62, 95% CI 1.13-2.32)...The differential effects observed among GLP-1RA agents emphasize the importance of personalized medicine approaches. These findings suggest significant implications for clinical practice and future research in both obesity management and cancer prevention.
  • ||||||||||  liraglutide / Generic mfg., metformin / Generic mfg., pioglitazone / Generic mfg.
    Review, Journal:  Glucose metabolism impairment in major depressive disorder. (Pubmed Central) -  Jan 12, 2025   
    Herein, we summarized the impairment of glucose metabolism and its pathophysiological mechanisms in patients with MDD. In addition, we briefly discussed potential pharmacological interventions for glucose metabolism to alleviate MDD, including glucagon-like peptide-1 receptor agonists, metformin, topical insulin, liraglutide, and pioglitazone, to encourage the development of new therapeutics.
  • ||||||||||  liraglutide / Generic mfg.
    Biomarker, Journal:  Biomarkers. (Pubmed Central) -  Jan 12, 2025   
    Interestingly, cerebral blood flow did not influence glucose metabolism. Microglia and astrocyte reactivity may contribute to an increase the cerebral glucose metabolism while neuronal loss and synaptic function may contribute to lower glucose metabolism measured by [18F]FDG in the early stages of Alzheimer's disease.
  • ||||||||||  Journal:  Drug Development. (Pubmed Central) -  Jan 12, 2025   
    The results demonstrate that enhanced BBB penetration of GLP-1 class drugs shows superior neuroprotective effects in a 3xtg mouse model of AD. This mirrors the observations from clinical trials in PD patients that show enhanced protection with drugs that can cross the BBB better.
  • ||||||||||  liraglutide / Generic mfg.
    Journal:  Drug Development. (Pubmed Central) -  Jan 12, 2025   
    This mirrors the observations from clinical trials in PD patients that show enhanced protection with drugs that can cross the BBB better. These findings highlight the potential of GLP-1 analogues in the treatment of Alzheimer's disease Authors: Edison P, Femminella GD, Ritchie C, Holmes C, Nowell J, Walker Z, Ridha B., Raza S, Livingston NR, Frangou E, Love S, Williams G, Lawrence R, Mcfarlane B, Archer H, Coulthard E, Underwood B. R, Koranteng P, Karim S, Bannister C, Perneczky R, Prasanna A, Junaid K, McGuinness B, Nilforooshan R, Macharouthu A, Donaldson A, Thacker S, Russell G, Malik N, Mate V, Knight L, Kshemendran S, Holscher C, Mansouri A, Mae Chester-Jones L, Holmes J, Tan T, Williams S, Brooks DJ, Harrison J, Hinz R, Tadros G, Passmore AP, Ballard C.